Identification of an effective chemotherapy and DNA damage response inhibitor combination for diffuse large b cell lymphoma

2022

Chemotherapy forms the backbone of treatment for Diffuse Large B Cell Lymphoma (DLBCL); however, <∼20% of tumors are chemoresistant. Inhibitors of the DNA damage response (DDR) show promise as chemosensitizers. We therefore set up an in-vitro screen to identify an optimal chemotherapy-DDR inhibitor (DDRi) combination in a panel of DLBCL cell lines.